Stachura, Paweł
Liu, Wei
Xu, Haifeng C.
Wlodarczyk, Agnès
Stencel, Olivia
Pandey, Piyush
Vogt, Melina
Bhatia, Sanil
Picard, Daniel
Remke, Marc
Lang, Karl S.
Häussinger, Dieter
Homey, Bernhard
Lang, Philipp A.
Borkhardt, Arndt
Pandyra, Aleksandra A.
Funding for this research was provided by:
José Carreras Foundation (DJCLS 07 R/2019, DJCLS 07 R/2019)
Forschungskommission , Medical faculty of Heinrich-Heine University Dusseldorf, Germany (2021-04, 2021-04)
Katharina-Hardt Foundation, Bad Homburg, Germany
Löwenstern e.V. Erkrath, Germany
Düsseldorf School of Oncology
the Ilsedore Luckow Stiftung, Dusseldorf, Germany
German Federal Office for Radiation Protection, München-Neuherberg, Germany
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 5 October 2022
Accepted: 27 July 2023
First Online: 15 August 2023
Declarations
:
: Experiments were performed under the authorization of LANUV in accordance with German law for animal protection.
: The authors declare no competing interests.
: HCX, PP, KSL, and PAL declare that they are involved in the development of LCMV for clinical application in oncology in cooperation with or as advisors to Abalos Therapeutics GmbH. The other authors declare no competing interests.